The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients

Gabriella Giancane 1, Claudio Lavarello 1, Angela Pistorio 2, Sheila K. Oliveira 3, Francesco Zulian 4, Ruben Cuttica 5, Michel Fischbach 6, Bo Magnusson 7, Serena Pastore 8, Roberto Marini 9, Silvana Martino 10, Anne Pagnier 11, Christine Soler 12, Valda Staņeva 13, Rebecca Ten Cate 14, Yosef Uziel 15, Jelena Vojinovic 16, Elena Fueri 1, Angelo Ravelli 18,19, Alberto Martini 18,19, Nicolino Ruperto 1* and for the Paediatric Rheumatology International Trials Organisation (PRINTO)

Abstract

Background: Prednisone (PDN) in juvenile dermatomyositis (JDM), alone or in association with other immunosuppressive drugs, namely methotrexate (MTX) and cyclosporine (CSA), represents the first-line treatment option for new onset JDM patients. No clear evidence based guidelines are actually available to standardize the tapering and discontinuation of glucocorticoids (GC) in JDM. Aim of our study was to provide an evidence-based proposal for GC tapering/discontinuation in new onset juvenile dermatomyositis (JDM), and to identify predictors of clinical remission and GC discontinuation.

Methods: New onset JDM children were randomized to receive either PDN alone or in combination with methotrexate (MTX) or cyclosporine (CSA). In order to derive steroid tapering indications, PRINTO/ACR/EULAR JDM core set measures (CSM) and their median absolute and relative percent changes over time were compared in 3 groups. Group 1 included those in clinical remission who discontinued PDN, with no major therapeutic changes (MTC) (reference group) and was compared with those who did not achieve clinical remission, without or with MTC (Group 2 and 3, respectively). A logistic regression model identified predictors of clinical remission with PDN discontinuation.

Results: Based on the median change in the CSM of 30/139 children in Group 1, after 3 pulses of methyl-prednisolone, GC could be tapered from 2 to 1 mg/kg/day in the first two months from onset if any of the CSM decreased by 50–94%, and from 1 to 0.2 mg/kg/day in the following 4 months if any CSM further decreased by 8–68%, followed by discontinuation in the ensuing 18 months. The achievement of PRINTO JDM 50–70-90 response after 2 months of treatment (ORs range 4.5–6.9), an age at onset > 9 years (OR 4.6) and the combination therapy PDN + MTX (OR 3.6) increase the probability of achieving clinical remission ($p < 0.05$).

(Continued on next page)
Background

Juvenile dermatomyositis (JDM) is a rare, autoimmune disease, primarily characterized by muscle and skin involvement. Less frequently, other systems like the gastrointestinal tract or lungs may be affected. Beside the significant decrease in the mortality rate of the disease in the last years, due to the introduction of glucocorticoids (GC) and disease modifying anti-rheumatic drugs (DMARDs), disease and drug related morbidity are still a major problem [1, 2]. Therapeutic approaches for adult patients with DM are not standardized [3–5], while those for children are essentially based on consensus and literature revision [6–10]. While GC still remain the mainstay of initial and long-term treatment in new-onset JDM despite their known adverse effects, a still open question is how to taper and discontinue GC in JDM patients. A recent randomized trial in new-onset untreated JDM, conducted by the Paediatric Rheumatology International Trials Organisation (PRINTO) [11, 12], showed that combined therapy with prednisone (PDN) and either methotrexate (MTX) or cyclosporine (CSA) was more effective than PDN alone. The PRINTO trial foresaw a consensus plan for GC tapering up to discontinuation which the participating centres could follow in clinical practice for the children enrolled in the study.

The primary objective of the present study was to provide an evidence-based proposal for GC tapering/discontinuation in new onset JDM patients, through the analysis of the PRINTO JDM trial. The secondary objective of the study was to identify predictors of GC discontinuation and clinical remission (CR) on medication.

Methods

Patients and study design

Data on new onset JDM children from the international, multicentre, randomised, open label, superiority PRINTO trial, whose details are available elsewhere, were analysed [11, 13]. In brief, children aged 18 years or younger, with newly diagnosed (PDN higher than 1 mg/kg for no more than 1 month allowed) probable or definite JDM, as per Bohan and Peter criteria [14, 15], were included in the trial. Major exclusion criteria were the presence of cutaneous or gastrointestinal ulceration or JDM-related pulmonary disease or cardiomyopathy. Patients were considered untreated if they received one month or less of PDN, no CSA or MTX.

Patients were randomized into 3 arms to either receive PDN alone, PDN plus CSA (PDN + CSA), or PDN plus MTX (PDN + MTX). The trial was divided into three parts: induction (first 2 months), maintenance (22 months), and extension (at least 3 years). The study database was locked after the last randomized patient had completed the induction and maintenance phases.

The study was firstly approved by the ethics committees/institutional review board of the main centre in Genoa, Italy (IRCCS Istituto Giannina Gaslini, Decision nr. 77 of 09/02/2006) and then by those of all participating centres in the trial (54 centres in the following countries: Argentina, Belgium, Brazil, Czech Republic, Denmark, France, Germany, Greece, Israel, Italy, Latvia, Mexico, Netherlands, Norway, Serbia, Slovakia, Slovenia, Sweden, United Kingdom, USA, Venezuela).

Glucocorticoid tapering/discontinuation PRINTO protocol

Before randomization to one of the 3 aforementioned arms, all children received three daily pulses of intravenous methylprednisolone (30 mg/kg per pulse, for a maximum amount of 1 g per pulse). In the induction phase, a consensus-based schema (NR, AR, AM and PRINTO members) suggested to administer 2 mg/kg per day of PDN or its equivalent (maximum 60 mg/day) divided in three doses per day (oral preferentially) for 1 month, then moved to morning daily dose, tapering the dose by 0.25 mg/kg every week to reach a daily dose of 1 mg/kg per day at the end of month 2. In the following 4 months PDN was supposed to be gradually tapered, as long as the patient remained clinically stable, up to a safe daily dose of 0.2 mg/kg by the end of month 6, which was maintained until the end of month 12. Afterwards, the dose of PDN was reduced to 0.1 mg/kg per day for further 6 months and then administered every other day until month 24. If a patient reached the status of inactive disease before month 24, PDN could be discontinued at physician’s discretion after discussion.
with the family. After the second year, treatment was at the discretion of the treating clinician.

Assessment and outcome
Clinical assessments to define patients’ response to therapy according to PRINTO criteria were performed every two months in the initial 6 months (monthly for safety) and then every 6 months up to year 2. Treatment failure (TF) was defined as the addition of CSA or MTX or any other DMARDs in any of the 3 groups or a major increase in their dose, or major increase in PDN dose or discontinuation of the assigned therapy for any reason (adverse events [AE], lost to follow-up, etc.).

Children were defined as responders if they demonstrated ≥20% (or 50/70/90%) improvement in ≥3 of the 6 variables of the JDM core set [16] with ≤1 variable worsening by > 30% (muscle strength excluded) [17, 18]. The 6 validated JDM PRINTO/American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) disease activity core set variables were: [16] the Childhood Myositis Assessment Scale (CMAS) (0 = worst; 52 = best); [19] physician’s global assessment (Physician global) of the patient’s overall disease activity on a 0–10 cm visual analogue scale (VAS) (0 = best; 10 = worst); [20] the Disease Activity Score (DAS) (0 = best; 20 = worst); [21] the cross-culturally adapted and validated version of the Childhood Health Assessment Questionnaire (C-HAQ) (0 = best; 3 = worst) [22, 23]; the parent’s global assessment of the child’s overall patient’s well-being (Parent Global) on a 10-cm VAS (0 = very well; 10 = very poor) [20, 22, 23]; the parent version of the physical summary score (PhS) of the Child Health Questionnaire (CHQ) [23, 24], with lower score indicating worse quality of life.

Patients were classified as being in a status of inactive disease if they met the validated PRINTO criteria for clinically inactive disease, which means at least 3 out of the following 4 criteria: creatine kinase ≤150, CMAS≤48, Manual Muscle Testing (MMT) ≤78, and PhyGlo VAS ≤ 0.2. We then verified our results through the proposed revised criteria by Almeida et al., which require mandatory PhyGlo VAS ≤ 0.2 [25, 26]. Clinical remission was defined as a status of inactive disease maintained for 6 continuous months on medication (clinical remission on medication) or 12 continuous months off any DMARDs/glucocorticoids (clinical remission off medication) [25].

Children in the trial were subsequently categorized into 3 mutually exclusive groups. Group 1 represented the reference standard for the best clinical outcome defined as those children on clinical remission on medication, with no TF, and no major deviation (±0.2 mg/kg PDN dose) from the assigned GC protocol, and who could continue PDN as per the suggested tapering schedule (CR Yes-TF no-PDN off). Group 1 was compared with those who did not achieve clinical remission, without TF (Group 2: CR no-TF no-PDN on or off) or with TF (Group 3: CR no-TF yes-PDN on or off). (Fig. 1).

Statistical analysis
Baseline and follow-up characteristics were summarized using descriptive statistics primarily by median (1st-3rd quartiles) changes in the PRINTO core set measures (CSM) in the first 6 and over 24 months. Proportions were analyzed by chi-square, or Fisher’s Exact test while for continuous variables t-test or ANOVA. Non-parametric ANOVA (Kruskal-Wallis test to compare 3 groups and Friedman test to compare repeated measures during time) has been applied in case of ordinal or non-normally distributed variables. For multiple hypothesis testing, Bonferroni’s correction was applied (1-(1-(1/p))^m), with n = 3 posterior comparisons.

For each core set variable, absolute change and “relative” percent change were calculated; the term “relative” refers to the fact that whenever the measure assumed the value of 0 at starting point, the percent change was calculated taking into account the range of the scale (example: the “relative” percent change of a measure changing from 0 to 2 on a 0–10 point-scale was equal to + 20% instead of the rough usual value of +100%) [27]. When missing data occurred for spare data among the different CSM, a mean value was calculated in case the missing value was between two available time points.

The association between the change in each core set variable, and the attainment of a status of GC discontinuation or CR on medication, were analyzed by multiple logistic regression, which used all significant variables in Table 1 and the different levels of PRINTO criteria for response at months 2, 4 and 6 to calculate the baseline-to-2-month change and the baseline-to-6-month change in each core set variable and as the dependent outcome clinical remission. Odds ratios (OR) with 95% confidence intervals (95% CI) were reported. Continuous variables were dichotomized according to the best cut-offs provided by the ROC analysis. [28] The pre-analysis hypothesis was that children able to demonstrate an earlier improvement in the PRINTO CSM or PRINTO criteria of response were more likely to achieve PDN discontinuation.

Data were entered into an Access XP database and analyzed with Excel XP (Microsoft), XLSTAT 6.1.9 Addinsoft, Statistica 6.0 (StatSoft, Inc), and Stata 7.0 (Stata Corporation).

Results
As shown in Figs. 1, 139 children from 54 centres in 22 countries were enrolled and randomized in the trial. Thirty (21.6%) patients were classified in Group 1 (CR yes-TF no-PDN off), 43 (30.9%) in Group 2 (CR no-TF no/PDN on or off), and 66 (47.5%) in
Group 3 (CR no-TF yes/PDN on or off). At baseline all the three groups had a high level of disease activity with no differences in the CSM (Table 1). Age at onset was the only variable with a statistically significant difference at baseline among the three groups with children in Group 1 (CR yes-TF no-PDN off) showing an older age at onset (9.5 versus 6.5 versus 6.9, p = 0.016).

Most of the patients in Group 1 (15 pt., 50%) received MTX + PDN, most of the patients in group 3 (30 pt., 45.5%) received PDN alone, while Group 2 was well balanced between the different drugs (9 pt. – 20.9% received PDN, 14 pt. – 32.6% PDN + MTX and 20 pt. – 46.5% PDN + CSA) in the middle (data not shown).

### Table 1 Baseline characteristic and PRINTO core set measures at onset of the study population

|                      | Group 1 (CR yes-TF no-PDN off) | Group 2 (CR no-TF no/PDN on or off) | Group 3 (CR no-TF yes/PDN on or off) | P |
|----------------------|-------------------------------|-------------------------------------|-------------------------------------|---|
| Age at onset (years) | 9.5 (6.2–12.3)                | 6.5 (3.3–9.8)                       | 6.9 (4.2–10)                        | 0.016 |
| Disease duration (mo) | 2.6 (1.3–4.7)                 | 2.6 (1.3–6.4)                       | 3.0 (1.5–4.8)                       | 0.94 |
| MD-global (0–10 †)   | 7.0 (6.0–8.0)                 | 6.0 (5.0–7.0)                       | 7.0 (5.0–8.0)                       | 0.17 |
| Parent global (0–10 †)| 6.0 (5.0–8.0)                 | 5.0 (3.5–7.0)                       | 5.4 (5.0–7.0)                       | 0.40 |
| CHAQ (0–3 †)         | 1.8 (1.1–2.6)                 | 1.8 (1.4–2.6)                       | 1.9 (1.3–2.5)                       | 0.94 |
| DAS (0–20 †)         | 13.0 (11.0–15.0)              | 13.0 (11.0–15.0)                    | 13.0 (11.0–15.0)                    | 0.80 |
| CMAS (0–52 ‡)        | 16.5 (13.0–33.0)              | 21.0 (14.0–35.0)                    | 20.7 (11.0–32.0)                    | 0.96 |
| MMT (0–80 ‡)         | 40.0 (30.0–60.0)              | 47.0 (35.0–58.0)                    | 48.0 (34.0–56.0)                    | 0.84 |
| CHAQ PhS (40–60 ‡)   | 19.8 (9.4–33.4)               | 12.7 (5.2–23.5)                     | 14.9 (8.1–22.4)                     | 0.16 |

Data are medians (1st 3rdquartiles). *P: P value refers to the non-parametric Analysis of Variance (Kruskal-Wallis test); MD-global: physician’s global assessment of the patient’s overall disease activity on a 0–10-cm visual analogue scale (VAS); Parent global: parents’ global assessment of the child’s overall patient’s well-being on a 10-cm VAS; DAS Disease Activity Score; CMAS Childhood Myositis Assessment Scale, MMT manual muscle testing; CHAQ cross-culturally adapted and validated version of the Childhood Health Assessment Questionnaire; † indicates that higher values correspond to a worse outcome; ‡ indicates that lower values correspond to a worse outcome.

Change over time in PRINTO core set measures

Figure 2 shows the trend over time of the PRINTO CSM and MMT in the 3 groups. Already after 2 months of treatment the 3 groups start to differentiate for all the disease activity measures in comparison to baseline. A statistically significant trend over time can be recognized from month 4 especially between Group 1 (CR yes-TF no-PDN off) and Group 3 (CR no-TF yes-PDN on or off), in particular for MD global, parent global, DAS, CMAS, MMT (all p values < 0.001) and CHAQ (p value = 0.002), with the exception of PhS that is very close to statistical significance and starts to be significant from month 12 onward.

When we considered patients in inactive disease according to the two different definitions (PRINTO criteria...
Fig. 2 Trend of the PRINTO CSM and MMT in the 3 groups of children with JDM. [A = MD-global: physician’s global assessment of the patient’s overall disease activity on a 0–10-cm visual analogue scale (VAS); B = Parent global: parents’ global assessment of the child’s overall patient’s well-being on a 10-cm VAS; C = DAS: Disease Activity Score (range 0–20); D = CHAQ: cross-culturally adapted and validated version of the Childhood Health Assessment Questionnaire (range 0–3); E = CMAS: Childhood Myositis Assessment Scale (range 0–52); F = MMT: manual muscle testing (range 0–80); G = PhS: physical summary score of the Child Health Questionnaire (range 40–60)]
[25] and Almeida’s criteria [26]), a complete overlap could be identified, since all the 30 patients from Group 1 (CR yes-TF no-PDN off) met both definitions having a Physician VAS ≤ 0.2.

Analyzing in more details the first 6 months from treatment start, while Groups 1 and 2 showed a similar trend in the improvement of disease activity parameters in the initial 2 to 6 months, Group 2 was not able to reach a status of clinical remission despite PDN being discontinued in 31/43 (72%) of the patients. Group 3 was even more different since only 20/66 (30%) were able to discontinue GC despite a TF which required a major change in treatment to control disease activity parameters (Figs. 1 and 2).

Table 2 shows the analysis of the median absolute change and relative percent change in disease activity parameters for the patients in the reference Group 1 (CR yes-TF no-PDN off). The median change in the CSM of Group 1 (CR yes-TF no-PDN off) was more pronounced in the initial 6 months of treatment (Table 2). In particular, an at least 50% change was present in all CSM already at month 2, with a marked CMAS change rising to 94% at month 2, and MD-global, MMT or DAS change of at least 3, 20 and 7 units, respectively. After 2 months from randomization and treatment start, the change in CSM became much less pronounced, with stable values after 6 months. With respect to the range of the scale for each core set variable, there was a considerable relative percent change in the different CSM over time (Table 2).

Predictors of glucocorticoid discontinuation in children with clinical remission on medication

The logistic regression model, including age at onset (the only statistically significant variable in Table 1), and the different levels of PRINTO criteria for response at months 2, 4 and 6, showed that the achievement of a PRINTO JDM 50–70−90 response at 2 months (OR range 4.5−6.9) from treatment start, an age at onset > 9 years (OR 4.6) and the combination therapy PDN + MTX (OR 3.6) increase the probability of achieving CR ($p < 0.05$) (Table 3).

The PRINTO evidence-based glucocorticoid tapering/discontinuation proposal

Figure 3 shows the PRINTO evidence-based treatment plan for GC tapering/discontinuation in children with new onset JDM. In brief, after 3 pulses of methyl-prednisolone, PDN could be tapered from 2 to 1 mg/kg/day in the first two months from onset if any of the CSM decrease by at least 50%, and from 1 to 0.2 mg/kg/day in the following 4 months if any of the CSM decreases further by 8–68%, followed by discontinuation over the next 18 months.

All children in group 1 followed the PDN consensus protocol for tapering treatment, as opposed to 5/43 (11.6%) and 50/60 (75.8%) in groups 2 and 3, respectively.

Discussion

The PRINTO JDM trial was a randomized study with a considerable number of new-onset JDM patients suited to provide an evidence-based proposal for GC tapering/discontinuation. It demonstrated that the use of combined therapy, MTX + PDN, is the best treatment option in these patients in terms of safety and efficacy. The PRINTO consensus-based steroid tapering protocol proposed in the randomized trial was tested against the strongest outcome of clinical remission off GC to extrapolate an evidence-based proposal for GC tapering/discontinuation.

Table 2 24 month-change in the PRINTO Core Set Measures in Reference Group 1 (N = 30)

| Predictor                  | 0 months | 0−2 months Absolute change (% change) | 2−4 months Absolute change (% change) | 4−6 months Absolute change (% change) | 6−24 months Absolute change (% change) |
|----------------------------|----------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
| MD evaluation (0–10 †)     | 7        | -3 ( 66.7%)                           | -1 ( 68.3%)                           | 0 (0%)                               | 0 (0%)                               |
| DAS (0–20 †)               | 13       | -7 ( 50%)                             | -2 ( 40%)                             | -1 ( 33.3%)                          | -1 ( 6.5%)                           |
| CMAS (0–52 ‡)              | 16.5     | +16 (+ 93.8%)                         | +4 (+ 15.8%)                          | +1 (+ 2.0%)                          | +1 (+ 3.4%)                          |
| MMT (0–80 ‡)               | 40       | +20 (+ 53.8%)                         | +6 (+ 8.1%)                           | +1.5 (+ 2.1%)                        | +1 (+ 1.3%)                          |
| Parent global (0–10 †)     | 6        | -4 ( 76.4%)                           | 0 (0%)                               | 0 (0%)                               | 0 (0%)                               |
| CHAQ (0–3 †)               | 1.8      | -1.2 ( 82.5%)                         | -0.1 ( 28.6%)                         | 0 (0%)                               | 0 (0%)                               |
| PHS (40–60 ‡)              | 19.8     | +14.2 (+ 53.8%)                       | +8.4 (+ 21.1%)                        | +3.2 (+ 7.3%)                        | +1.9 (+ 4.3%)                        |

Group 1: clinical remission yes- treatment failure no- prednisone off, MD-global: physician’s global assessment of the patient’s overall disease activity on a 0–10-cm visual analogue scale (VAS); Parent global: parents’ global assessment of the child’s overall patient’s well-being on a 10-cm VAS; DAS Disease Activity Score, CMAS Childhood Myositis Assessment Scale, MMT manual muscle testing, CHAQ cross-culturally adapted and validated version of the Childhood Health Assessment Questionnaire; † indicates that higher values correspond to a worse outcome; ‡ indicates that lower values correspond to a worse outcome.
At baseline, disease activity was comparable in all the three groups of patients analyzed, but the group of patients with an older age showed a better outcome as confirmed by the logistic regression model. After treatment initiation, the three groups significantly differentiated over time, with a clear trend given by a sharp decrease in disease activity parameters, which was particularly evident when the reference Group 1 was compared with the other two groups. Most important, the differentiation in disease activity started very early (already after 2 months), and became apparent within the first 6 months of observation. This means that a trend toward a fast decrease in disease activity parameters can be recognizable in the early phase of treatment and can be used as clinical predictor of a better outcome. While group 1 and 2 showed a similar trend in the decrease of disease activity parameters in the initial 2 to 6 months, they represent a different clinical phenotype according to clinical remission, so they could not be combined. Group 3 had the worst outcome since just one third was able to discontinue glucocorticoids, but with the need to introduce a major change in treatment to control disease activity.

The analysis was therefore focused on Group 1 (CR yes, TF no, PDN off), as the reference standard group in the trial population. Indeed this group showed a greater improvement in disease activity, which was already evident after 2 months. Based on the observation of this group, we could provide an evidence-based proposal on how to taper prednisone, up to discontinuation, in new onset JDM patients using quantitative cut-offs of CSM, that foresee a rapid decrease in few months to the dose of PDN which is thought to limit effects on growth [29]. Indeed, the knowledge of lower cut-offs for the single core set parameters, whose achievement may allow the clinician to modify therapy, is a practical indicator for the physician who has to decide in the everyday clinical practice how to use the JDM outcome measures to taper GC.

In the last years, literature provided consensus-based recommendations, aimed to facilitate diagnosis and

### Table 3 Predictors of clinical remission and prednisone discontinuation

| Predictor                                           | Odds Ratio (95% CI) | p-value |
|-----------------------------------------------------|---------------------|---------|
| Responder at 2 months                               |                     |         |
| Printo-50 (vs. not responder/Printo-20)             | 5.41 (1.37–21.32)   | 0.0076  |
| Printo-70 (vs. not responder/Printo-20)             | 6.90 (1.91–24.99)   |         |
| Printo-90 (vs. not responder/Printo-20)             | 4.46 (1.08–18.38)   |         |
| Onset age > 8.53 years (vs. ≤ 8.53 years)           | 4.64 (1.69–12.71)   | 0.0017  |
| Therapy group: PDN + MTX (vs. PDN/PDN + CSA)        | 3.63 (1.30–10.09)   | 0.0116  |
| AUC of the model                                    | 0.80                |         |

PDN prednisone, MTX methotrexate, CSA Cyclosporine. OR Odds Ratio, 95% CI 95% Confidence Interval; p²: Likelihood Ratio test

At baseline, disease activity was comparable in all the three groups of patients analyzed, but the group of patients with an older age showed a better outcome as confirmed by the logistic regression model. After treatment initiation, the three groups significantly differentiated over time, with a clear trend given by a sharp decrease in disease activity parameters, which was particularly evident when the reference Group 1 was compared with the other two groups. Most important, the differentiation in disease activity started very early (already after 2 months), and became apparent within the first 6 months of observation. This means that a trend toward a fast decrease in disease activity parameters can be recognizable in the early phase of treatment and can be used as clinical predictor of a better outcome. While group 1 and 2 showed a similar trend in the decrease of disease activity parameters in the initial 2 to 6 months, they represent a different clinical phenotype according to clinical remission, so they could not be combined. Group 3 had the worst outcome since just one third was able to discontinue glucocorticoids, but with the need to introduce a major change in treatment to control disease activity.

The analysis was therefore focused on Group 1 (CR yes, TF no, PDN off), as the reference standard group in the trial population. Indeed this group showed a greater improvement in disease activity, which was already evident after 2 months. Based on the observation of this group, we could provide an evidence-based proposal on how to taper prednisone, up to discontinuation, in new onset JDM patients using quantitative cut-offs of CSM, that foresee a rapid decrease in few months to the dose of PDN which is thought to limit effects on growth [29]. Indeed, the knowledge of lower cut-offs for the single core set parameters, whose achievement may allow the clinician to modify therapy, is a practical indicator for the physician who has to decide in the everyday clinical practice how to use the JDM outcome measures to taper GC.

In the last years, literature provided consensus-based recommendations, aimed to facilitate diagnosis and
treatment of JDM patients through multiple meetings among clinicians and researchers. In this context the Children’s Arthritis and Rheumatology Research Alliance (CARRA) proposed consensus treatment plans for the management of JDM patients with recent onset [9, 30]. The use of GC in JDM was a main point of the consensus, with the specialists providing indications on the timing and modality of steroid tapering and use. Despite the longest period for GC discontinuation proposed by this study, and differently from the CARRA recommendation, we think that it can be a valuable option for GC tapering/discontinuation due to the evidence of strong outcome (clinical remission off GC) in the PRINTO cohort, the already reported acceptable safety profile [11, 12], and the possibility to achieve after only 6 months the safe dose of 0.2 mg/kg/day, so avoiding long PDN exposure and subsequent side effects. Moreover, the PRINTO JDM trial represents a large source of prospective data on a very rare condition in pediatrics, which still needs to be clarified in multiple aspects. This allows observations on real patients’ data with the advantage of reporting evidence-based information. Differently from CARRA recommendations, nevertheless, our treatment plan provides evidence that it is possible to achieve the steroid dose of 0.2 mg/kg/day, considered safer especially for growth impairment, within 6 months instead of 9, with good clinical control, so avoiding long PDN exposure and subsequent side effects. In 2016, a similar effort, conducted by a European initiative called Single Hub and Access point for pediatric Rheumatology in Europe (SHARE) initiated in 2012 to provide diagnostic and therapeutic regimens for all the pediatric rheumatic diseases, yielded, through a consensus process, recommendations on diagnosis and therapy in JDM, including consensus on steroid use, to be reduced as the patient shows clinical improvement [10]. The PRINTO proposal for tapering will allow pediatric rheumatologist to take advantage of concrete quantitative indications about how to use GC and when and how to taper them in clinical practice based on the change in individual CSM. The importance of evaluating quantitatively CSM in the JDM patient follow-up is consequently a major point and should be performed by all the pediatric rheumatologists at each visit [16–18, 31–40].

The results of this study are important also in light of future treatment plans which apply a treat-to-target strategy, already proposed in the management of juvenile idiopathic arthritis (JIA) [41]. Indeed, the identification that the attainment of at least JDM PRINTO 50 criteria of response in 2 months or an improvement by at least 50% in CSM (90% in CMAS), especially in children treated with the combination of PDN + MTX, is a very early predictor of clinical remission and steroid discontinuation, favors the hypothesis that earlier and more aggressive treatment might lead to a better outcome. The results of this study might allow the pediatric rheumatologists to tell patients and families if there is a higher probability of achieving remission according to the course of the disease in the first months from treatment start. Looking from a different perspective a patient without these characteristics could be considered at higher risk of a worse disease course and deserve therefore more aggressive treatments.

This work has some limitations that should be considered by the pediatric rheumatologist, willing to follow our proposal. First of all, a limitation of our study may be represented by the long period of administration of steroids, whose side effects may prevent the use of this medication. Nevertheless, the cumulative dose of PDN per kilo of body weight was 250.88 mg for both group 1 and 2, and 250.9 for group 3, (data not shown) which means that the cumulative dose of GC was similar for all the three groups, not modifying the PDN-related side effects. Moreover, this steroid schedule allows to reach what is considered in all trials in poly-articular course JIA a safer dose of PDN (0.2 mg/kg/day or 10 mg/day whichever is lower) [42–46], in a short time (6 months), continuing just with a very low dose up to month 24, when discontinuation may be attempted. Finally, in an independent PRINTO series of 275 patients collected worldwide, 41/98 (41.8%) of children with recent onset JDM were still on glucocorticoid treatment after 24 months from disease onset. [5]

Up to now, we cannot compare our results with other randomized trials on steroid tapering/discontinuation in new-onset JDM patients. The lack of alternative steroid protocols, provided by evidence-based trials, or standard consensus on glucocorticoid therapy for both intravenous and oral induction, does not allow further considerations about safety and efficacy of the proposed steroid tapering schedule neither comparison with a shorter steroid course, likely to be considered preferable. Since the purpose of the present work was not to provide recommendations on the use of glucocorticoids in JDM, but to propose a possible protocol for glucocorticoids tapering withdrawal in new-onset JDM patients, the proposed protocol may help the pediatric rheumatologist to deal at onset with such a challenging disease.

Another major point of discussion is the presence of around 50% of patients in Group 1 on PDN + MTX, which is the most effective treatment group in the PRINTO JDM trial [11]. This could have induced an improvement in disease activity, not due to the proposed glucocorticoid tapering protocol, but to the combination therapy with MTX as also underlined by the logistic regression model. It should be noted, however, that one third of patients in the other two groups, received the same combination of PDN + MTX.
Another limit of the present work is the small comparative sample size and reference group. However this should be read in light of the rarity of the disease and the lack of prospective data on new onset JDM patients which makes our results noteworthy.

Finally, it is notable that a large percentage of patients (42%) failed to discontinue GC according to the proposed weaning schedule. If we consider that all the three groups of patients presented at baseline with the same demographic and clinical features (Table 1), except for a slightly increased disease duration in Group 3, and since MTX therapy is well-proven in efficacy in JDM patients [11], this should be read as a warning in considering MTX at the very beginning of the JDM patient history.

The lack of change in the CSM after 12 months in Group 1 and 2 in particular may raise the need of new trials testing two different strategies for steroid tapering with the main aim to shorten the on-therapy period. In fact, in order to either confirm our results or propose new treating strategies in new onset JDM patients, there is the need of new comparative studies in pediatrics.

Conclusions

This study provides a steroid tapering plan in new-onset JDM patients. In particular, we propose evidence-based specific quantitative cut-offs for glucocorticoids tapering/discontinuation based on the change in the CSM in the initial 6 months of treatment as well as in the overall response to treatment and we identify early predictors of remission, to be used in daily practice and in future clinical trials by pediatric rheumatologists.

Abbreviations

ACR: American College of Rheumatology; AE: Adverse event; CARRA: Children’s Arthritis and Rheumatology Research Alliance; CHAQ: Childhood Health Assessment Questionnaire; CHQ-Phi: parent version of the physical summary score; CMAS: Childhood Myositis Assessment Scale; CR: Clinical remission; CSA: Cyclosporine; CSM: Core set measure; DAS: Disease Activity Score; DMARDs: Disease-modifying anti-rheumatic drugs; EULAR: European League Against Rheumatism; GC: Glucocorticoids; JDM: Juvenile dermatomyositis; MD: Global: Physician Global Activity; MMT: Manual muscle testing; MTX: Methotrexate; PON: Prednisone; PRINTO: Paediatric Rheumatology International Trials Organisation; SHARE: Single Hub and Access point for Arthritis and Rheumatology Research Alliance; CHAQ: Childhood Health Assessment Questionnaire; VAS: Visual analog scale.

Acknowledgements

We thank the children and their families who actively agreed to take part in the study and the medical and health care staff at the PRINTO participating centers. A special thank goes to the staff of the PRINTO Coordinating Centre, Simona Angioloni, Luca Villa and Irene Gregorini, for their administrative and technical support within the trial.

Funding

The study was funded by the The Italian Agency of Drug Evaluation (AIFA contract number FARMS2EBTS), the IRCCS Istituto Giannina Gaslini, Genoa, Italy and the Myositis Association. We declare that there are no direct commercial sources to be disclosed for the work reported in the manuscript.

Availability of data and materials

The datasets generated and/or analysed during the current study are available in the PRINTO repository (www.printo.it). The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

GG, AP and NR gave substantial contributions to study conception and design and to analysis and interpretation of data. CL, SKO, FZ, RC, MF, BM, SP, RM, SM, AP, CS, VS, RTC, YU, JV, EF, AR, AM, NR drafted the first and subsequent drafts of the article; All authors (GG, CL, AP, SKO, FZ, RC, MF, BM, SP, RM, SM, AP, CS, VS, RTC, YU, JV, EF, AR, AM, NR) revised the article critically for important intellectual content and gave final approval of the version of the article to be published.

Ethics approval and consent to participate

The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Guidelines for Good Clinical Practice and local regulations. An institutional review board or independent ethics committee at each site approved the protocol, consent form and any other written information provided to patients or their legal representatives.

Consent for publication

All patients or their legal representatives gave written informed consent/assent prior to study entry as per local requirements of the participating centres.

Competing interests

Gabriella Giancane has no conflicts of interest to disclose. Claudio Lavarello has no conflicts of interest to disclose. Angela Pistorio has no conflicts of interest to disclose. Sheila K. Oliveira has no conflicts of interest to disclose. Francesco Zulian has no conflicts of interest to disclose. Ruben Cuttica reports speaker bureau, consulting and Principal Investigator for Abbvie, BMS, Centocor, GSK, Lilly, Pfizer, Roche, Sanofi, UCB (< 10.000 USD each). Michel Fischbach has no conflicts of interest to disclose. Bo Magnusson has no conflicts of interest to disclose. Serena Pastore has no conflicts of interest to disclose. Roberto Marini has no conflicts of interest to disclose. Silvana Martino has no conflicts of interest to disclose. Anne Pagnier has no conflicts of interest to disclose. Valda Šaņeviča has no conflicts of interest to disclose. Erik Søndergaard has no conflicts of interest to disclose. Valeria Ten Cate has no conflicts of interest to disclose. Yosef Uziel has received speaker’s bureaus or consulting fees from: Abbvie, Pfizer, Novartis (< 10.000 USD each). Jelena Vojinovic has no conflicts of interest to disclose. Elena Fueri has no conflicts of interest to disclose. Angelo Ravelli has received speaker’s bureaus or consulting fees from: AbbbVie, BMS, Pfizer.

Ruben Cuttica reports speaker bureau, consulting and Principal Investigator for AbbbVie, BMS, Pfizer, Novartis. From < 10.000 USD each for Abbvie, BMS, Centocor, GSK, Lilly, Pfizer, Roche, Sanofi, UCB (< 10.000 USD each).

Alberto Martini does not have any conflict of interest to declare since March 2016, when he became the Scientific Director of the Gaslini Institute because this role does not allow him to render private consultancy resulting in personal income. AM performed consultancy activities on behalf of the Gaslini Institute for Abbvie, Boehringer, Novartis, and R-Pharm (< 10.000 USD each).

Niccolò Ruperto has received honoraria for consultancies or speaker bureaus (< 10.000 USD each) from the following pharmaceutical companies in the past 3 years: Ablynx, AbbbVie, AstraZeneca-Medimmune, Biogen, Boehringer, Bristol Myers and Squibb, Eli-Lilly, EMD Serono, Glaxo Smith and Kline, Hoffmann-La Roche, Janssen, Merck, Novartis, Pfizer, R-Pharma, SanofiServier, Sinerigie, Sobi and Takeda.

The Gaslini Hospital, where NR works as full-time public employee, has received contributions (> 10.000 USD each) from the following pharmaceutical companies in the last 3 years: BMS, Eli-Lilly, GlaxoSmithKline, F. Hoffmann-La Roche, Janssen, Novartis, Pfizer, Sobi. This funding has been reinvested for the research activities of the hospital in a fully independent manner, without any commitment with third parties.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Author details
1IRCCS Istituto Giannina Gaslini, Clinica Pediatrica – Reumatologia, PRINTO, Genoa, Italy. 2IRCCS Istituto Giannina Gaslini, Servizio di Epidemiologia e Biostatistica, Genoa, Italy. 3Institute of Pauciherie and Paediatrici cartalio Gestes (IPPMG), Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. 4Department of Woman and Child Health, University of Padua, Padua, Italy. 5Hospital General de Ninos Pedro de Elizalde, Unidad de Reumatologia, Buenos Aires, Argentina. 6Hospital Universitario de la Guipúzcoa, Donostia, Spain. 7University of San Diego, La Jolla, CA, USA. 8IRCCS Burlo Garofolo, Institute for Maternal and Child Health, Trieste, Italy. 9Department of Pediatrics, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, Brazil. 10Clinica Pediatrica, Università degli Studi di Torino, Torino, Italy. 11Medicice Infantile, Centre Hospitalier Universitaire Grenoble-Alpes (CHU de Grenoble), Grenoble, France. 12Service de Pédriatric, Hôpital de l’Arche, Nice, France. 13Department of Pediatrics, Bern University, University of Geneva, Geneva, Switzerland. 14Department of Pediatrics, Karolinska University Hospital, Stockholm, Sweden. 15IRCCS Burlo Garofolo, Institute for Maternal and Child Health, Trieste, Italy. 16Department of Pediatric Immunology and Rheumatology, Faculty of Medicine, University of Nis, Nis, Serbia. 17Clinic of Pediatrics, Department of Pediatric Rheumatology, Clinical Center Nis, Nis, Serbia. 18IRCCS Istituto Giannina Gaslini, Clinica Pediatrica – Reumatologia, Genoa, Italy. 19Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infanitl (DiNOGMI), Università degli Studi di Genova, Genoa, Italy.

Received: 12 February 2019 Accepted: 2 May 2019

Published online: 22 May 2019

References
1. Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken ). 2009;61(1):63–72.
2. Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;371(9631):2001–12.
3. Odds CV, Rider LG, Reed AM, Ruperto N, Brunnert H, Koneru B, et al. International consensus guidelines for trials of therapy in the idiopathic inflammatory myopathies. Arthritis Rheum. 2005;52(9):2607–15.
4. Gordon PA, Winer JB, Hoogendijk JE, Choy EH. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev. 2012;(8):CD003643.
5. Hasija R, Pistorio A, Ravelli A, Demirkaya E, Khubchandani R, Guseinova E, et al. Therapeutic Approaches in the Treatment of Juvenile Dermatomyositis in Patients With Recent-Onset Disease and in Those Experiencing Disease Flare. Arthritis Rheum 2017;69(1):151–5.
6. Almeida B, Campanilho-Marques R, Arnold K, Pilkington C, Ballinger SH, Boywer SL, Giannini EH, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies - II. The childhood myositis assessment scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum. 1999 Oct;42(10):2213–9.
7. Rider LG, Feldman BM, Perez MD, Ruperto N, Pilkington C, Zemel LS, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. I. Physician, parent, and patients global assessments. Arthritis Rheum. 1997;40(11):1976–83.
8. Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum. 2003 Feb 15;49(1):17–5.
9. Singh G, Ashriva BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1994;37:1761–9.
10. Ruperto N, Ruperto A, Pistorio A, Malattia C, Cavuto S, Child Health Outcome Questionnaire for Juvenile Dermatomyositis (CHQ-JDM). A cross-cultural validation study in children with idiopathic inflammatory myopathies. J Pediatr. 2003 Dec;143(6):912–9.
11. Stringer E, Bohnsack J, Bowyer SL, Griffin TA, Huber AM, Lang B, et al. Therapeutic Approaches in the Treatment of Juvenile Dermatomyositis. Arthritis Care Res. 2008;60(1):29–39.
12. Metz CE. Basic principles of ROC analysis. Semin Nucl Med. 1978 Oct(8):283–98.
13. Ribeiro D, Zawadynski S, Petitt L, Chevallet T, Girardin E, Parvex P. Effect of glucocorticoids on growth and bone mineral density in children with nephrotic syndrome. Eur J Pediatr. 2015;174(7):911–7.
14. Stringer E, Bohnsack J, Bowyer SL, Griffin TA, Huber AM, Lang B, et al. Treatment approaches to juvenile dermatomyositis (JDM) across North America: the childhood arthritis and rheumatology research Alliance (CARRA) JDM treatment survey. J Rheumatol. 2010 Sep;37(9):1953–61.
15. Ruperto N, Pistorio A, Trail L, Ferti C, Sala E, Martini A. Clinical assessment in juvenile dermatomyositis. Autoimmun Rev. 2006 May;5(3):197–203.
rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an international myositis assessment and clinical studies group/Paediatric rheumatology international trials organisation collaborative initiative. Ann Rheum Dis. 2017 May;76(5):792–801.

33. Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM, et al. American College of Rheumatology/European league against rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an international myositis assessment and clinical studies group/Paediatric rheumatology international trials organisation collaborative initiative. Arthritis Rheumatol 2016;69(5):898–910.

34. Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, et al. 2016 American College of Rheumatology/European league against rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: an international myositis assessment and clinical studies group/Paediatric rheumatology international trials organisation collaborative initiative. Arthritis Rheumatol 2017 May. 2016;69(5):911–23.

35. Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, et al. American College of Rheumatology/European league against rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: an international myositis assessment and clinical studies group/Paediatric rheumatology international trials organisation collaborative initiative. Ann Rheum Dis. 2017 May;76(5):782–91.

36. Senecal JL, Raynauld JP, Troyanov Y. Editorial: a new classification of adult autoimmune myositis. Arthritis Rheumatol. 2017 May;69(5):878–84.

37. Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res. 2010;15(6):63–72.

38. Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CADSI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skinex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S118–57.

39. Rider LG, Ruperto N, Pistorio A, Erman B, Bayat N, Lachenbruch PA, et al. 2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects. Rheumatology (Oxford). 2017 Nov 15;66(11):1884–93.

40. Varnier GC, Rosina S, Ferrari C, Consolaro A, Bovis F, et al. Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care. Arthritis Care Res (Hoboken). 2017.

41. Ravelli A, Consolaro A, Homeff G, Laxer RM, Lovell DJ, Wulffraat NM, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018 Jun;77(6):819–28.

42. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group N Engl J Med. 2000;342(11):763–9.

43. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Abatacept in children with polyarticular juvenile rheumatoid arthritis. Arthritis Care Res. 2007;15:63(Suppl 1):S118–57.

44. Brunner HI, Ruperto N, Tzaribachev N, Horneff G, Chasnyk VG, Panaviene V, et al. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis. 2017; May 15[Epub ahead of print].